In addition, the VASH1/2-SVBP carboxypeptidases have been recently identified as a tubulin detyrosinating complexes20,21 suggesting that also drugs able to modulate tubulin carboxypeptidase activity may offer a valuable new approach for therapeutic intervention in Alzheimer’s disease. Here, VASH1 is linked to early-onset autosomal dominant Alzheimer disease.